Processa Pharmaceuticals (NASDAQ:PCSA) Now Covered by Analysts at HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Processa Pharmaceuticals (NASDAQ:PCSA) Receives New Coverage from Analysts at HC Wainwright themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) CEO David Young bought 40,000 shares of Processa Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The shares were acquired at an average cost of $0.80 per share, for a total transaction of $32,000.00. Following the completion of the transaction, the chief executive officer now […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price target decreased by Benchmark from $9.00 to $4.00 in a research report released on Tuesday morning, Benzinga reports. Benchmark currently has a speculative buy rating on the stock. A number of other analysts have also recently issued reports on PCSA. Oppenheimer cut their price objective on […]
Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price objective reduced by Oppenheimer from $5.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Processa Pharmaceuticals’ Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at […]